The aim of this study is to investigate the effect of oral ketone ester administration on sleep architecture. To investigate this, the investigators use a randomised, placebo-controlled, cross-over research design. The study comprises three experimental sessions, each separated by a one-week washout period. Two of the three experimental sessions consist of a 120 minutes cycling endurance training session (ET) two hours after breakfast and an evening high-intensity-interval training (HIIT) ending one hour before bedtime. After each training session, and 30 minutes before sleeptime, subjects receive a ketone ester or a control drink . To investigate the effects of strenuous exercise on sleep alone, an additional experimental session without exercise is added. Before bedtime, a venous blood sample is taken to evaluate hormones playing an important role in sleep regulation. During the experimental sessions, the subjects sleep in a sleep facility to evaluate quality of sleep. Time spent in different sleep phases is measured via polysomnography (PSG). Urine output throughout the day and night will be collected for measurement of urinary excretion of adrenaline and noradrenaline as an index of intrinsic sympathetic activity.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
11
A dose of 25g of ketone ester after each training session and 30 minutes before sleeptime. The total dose is 75g of ketone ester.
Collagen peptan (3g) mixed with 1 mM bitter sucrose octaacetate and 20ml of pure water. A dose of 25g of placebo drink is provided after each training session and 30 minutes before sleeptime. The total dose is 75g of placebo drink.
A 120 minutes cycling endurance training session (ET) two hours after breakfast and an evening high-intensity-interval training (HIIT) ending one hour before bedtime
Exercise Physiology Group
Leuven, Belgium
Total sleep time
Change in total sleep time between conditions as evaluated with polysomnography
Time frame: Between each condition, interspersed each time with a one-week wash-out period (The total duration of the measurements is two weeks)
Urinary nocturnal adrenaline excretion
Change in urinary nocturnal adrenaline excretion between conditions
Time frame: Between each condition, interspersed each time with a one-week wash-out period (The total duration of the measurements is two weeks)
Urinary nocturnal noradrenaline excretion
Change in urinary nocturnal adrenaline excretion between conditions
Time frame: Between each condition, interspersed each time with a one-week wash-out period (The total duration of the measurements is two weeks)
Total rapid-eye-movement sleep
Change in total rapid-eye-movement sleep between conditions as evaluated with polysomnography
Time frame: Between each condition, interspersed each time with a one-week wash-out period (The total duration of the measurements is two weeks)
Total non-rapid-eye-movement sleep
Change in total non-rapid-eye-movement sleep between conditions as evaluated with polysomnography
Time frame: Between each condition, interspersed each time with a one-week wash-out period (The total duration of the measurements is two weeks)
Total slow-wave sleep
Change in total slow-wave sleep between conditions as evaluated with polysomnography
Time frame: Between each condition, interspersed each time with a one-week wash-out period (The total duration of the measurements is two weeks)
Plasma adrenaline concentration
Change in plasma adrenaline concentration between conditions
Time frame: Between each condition, interspersed each time with a one-week wash-out period (The total duration of the measurements is two weeks)
Plasma noradrenaline concentration
Change in plasma noradrenaline concentration between conditions
Time frame: Between each condition, interspersed each time with a one-week wash-out period (The total duration of the measurements is two weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.